Literature DB >> 33396774

Tumor-Targeting Peptides Search Strategy for the Delivery of Therapeutic and Diagnostic Molecules to Tumor Cells.

Maria D Dmitrieva1, Anna A Voitova1, Maya A Dymova1, Vladimir A Richter1, Elena V Kuligina1.   

Abstract

BACKGROUND: The combination of the unique properties of cancer cells makes it possible to find specific ligands that interact directly with the tumor, and to conduct targeted tumor therapy. Phage display is one of the most common methods for searching for specific ligands. Bacteriophages display peptides, and the peptides themselves can be used as targeting molecules for the delivery of diagnostic and therapeutic agents. Phage display can be performed both in vitro and in vivo. Moreover, it is possible to carry out the phage display on cells pre-enriched for a certain tumor marker, for example, CD44 and CD133.
METHODS: For this work we used several methods, such as phage display, sequencing, cell sorting, immunocytochemistry, phage titration.
RESULTS: We performed phage display using different screening systems (in vitro and in vivo), different phage libraries (Ph.D-7, Ph.D-12, Ph.D-C7C) on CD44+/CD133+ and without enrichment U-87 MG cells. The binding efficiency of bacteriophages displayed tumor-targeting peptides on U-87 MG cells was compared in vitro. We also conducted a comparative analysis in vivo of the specificity of the accumulation of selected bacteriophages in the tumor and in the control organs (liver, brain, kidney and lungs).
CONCLUSIONS: The screening in vivo of linear phage peptide libraries for glioblastoma was the most effective strategy for obtaining tumor-targeting peptides providing targeted delivery of diagnostic and therapeutic agents to glioblastoma.

Entities:  

Keywords:  CD133; CD44; cancer stem cells (CSCs); fluorescence-activated cell sorting (FACS); glioblastoma; immunocytochemistry; phage display; tumor-targeting peptides

Mesh:

Substances:

Year:  2020        PMID: 33396774      PMCID: PMC7796297          DOI: 10.3390/ijms22010314

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  17 in total

Review 1.  Flexible or fixed: a comparative review of linear and cyclic cancer-targeting peptides.

Authors:  Áron Roxin; Gang Zheng
Journal:  Future Med Chem       Date:  2012-08       Impact factor: 3.808

2.  In vivo phage display selection of an ovarian cancer targeting peptide for SPECT/CT imaging.

Authors:  Mette Soendergaard; Jessica R Newton-Northup; Susan L Deutscher
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-09-06

Review 3.  Therapeutic peptides: Historical perspectives, current development trends, and future directions.

Authors:  Jolene L Lau; Michael K Dunn
Journal:  Bioorg Med Chem       Date:  2017-07-01       Impact factor: 3.641

4.  Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma.

Authors:  Shilpa Lingala; Yi-Yao Cui; Xiaoli Chen; Boris H Ruebner; Xiao-Feng Qian; Mark A Zern; Jian Wu
Journal:  Exp Mol Pathol       Date:  2010-05-16       Impact factor: 3.362

5.  CD133+CD44+ population efficiently enriches colon cancer initiating cells.

Authors:  Naotsugu Haraguchi; Masahisa Ohkuma; Hiroyuki Sakashita; Shinji Matsuzaki; Fumiaki Tanaka; Koshi Mimori; Yukio Kamohara; Hiroshi Inoue; Masaki Mori
Journal:  Ann Surg Oncol       Date:  2008-07-29       Impact factor: 5.344

6.  Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors.

Authors:  Sergio Rutella; Giuseppina Bonanno; Annabella Procoli; Andrea Mariotti; Maria Corallo; Maria Grazia Prisco; Adriana Eramo; Chiara Napoletano; Daniela Gallo; Alessandro Perillo; Marianna Nuti; Luca Pierelli; Ugo Testa; Giovanni Scambia; Gabriella Ferrandina
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

7.  Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity.

Authors:  Daniel V Brown; Gulay Filiz; Paul M Daniel; Frédéric Hollande; Sebastian Dworkin; Stephanie Amiridis; Nicole Kountouri; Wayne Ng; Andrew P Morokoff; Theo Mantamadiotis
Journal:  PLoS One       Date:  2017-02-27       Impact factor: 3.240

Review 8.  Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets.

Authors:  Olivia G Taylor; Joshua S Brzozowski; Kathryn A Skelding
Journal:  Front Oncol       Date:  2019-09-26       Impact factor: 6.244

Review 9.  Phage display screening of therapeutic peptide for cancer targeting and therapy.

Authors:  Phei Er Saw; Er-Wei Song
Journal:  Protein Cell       Date:  2019-05-28       Impact factor: 14.870

10.  Tumor-Specific Peptide, Selected from a Phage Peptide Library, Enhances Antitumor Activity of Lactaptin.

Authors:  Anna A Nemudraya; Anna A Makartsova; Alexandr S Fomin; Anna A Nushtaeva; Olga A Koval; Vladimir A Richter; Elena V Kuligina
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

View more
  2 in total

1.  Identification and Validation of Immune-Related Biomarker Gene and Construction of ceRNA Networks in Septic Cardiomyopathy.

Authors:  Jingru Li; Xinyu Wu; Chaozhong Li; Guihu Sun; Peng Ding; Yanyan Li; Ping Yang; Min Zhang; Luqiao Wang
Journal:  Front Cell Infect Microbiol       Date:  2022-06-16       Impact factor: 6.073

2.  Structural Requirements for the Binding of a Peptide to Prohibitins on the Cell Surface of Monocytes/Macrophages.

Authors:  Qindong Zhang; Anniken Olberg; Mouldy Sioud
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.